Delcath is dedicated to revolutionizing the treatment of patients with cancer in their liver.

Delcath is dedicated to revolutionizing the treatment of patients with cancer in their liver.

Delcath Systems, Inc. is a commercial-stage interventional oncology company aiming to be the leader in targeted, safe and effective minimally-invasive treatments for patients with cancers in the liver.

Current options for patients with liver metastases are limited.

Delcath is committed to finding a different path.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. At Delcath, we look beyond the ordinary and strive for excellence in all that we do.

The Problem

Liver cancers affect 1.2 million people globally every year. Additional treatment options are required for these patients.

Our Solution

Delcath is an interventional oncology company with a recently FDA approved treatment for adult patients with metastatic Uveal Melanoma. In the United States, our product is called HEPZATO KIT™ (melphalan) for Injection/Hepatic Delivery System (HDS).

In Europe, our commercial, medical device product is called CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP).

For more information about our treatments, please visit: